Report
Valens Research

JNJ - Embedded Expectations Analysis - 2020 12 02

Johnson & Johnson (JNJ:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with an 17.9x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management may have concerns about TREMFYA, margins, and non-US markets

Specifically, management may be exaggerating the capabilities of TREMFYA, the potential of subcutaneous formulation for multiple myeloma, and the progress of their pipeline with the FDA. In addition, they may be concerned about continued pressure from competition in the US, the continued impact from the sell-through of product stocking in China, and the varying recovery in non-US markets. Furthermore, they may lack confidence in their ability to improve margins, transform autoantibody-related diseases with nipocalimab, and maintain their ERLEADA growth
Underlying
Johnson & Johnson

Johnson & Johnson is a holding company engaged in the research and development, manufacture and sale of a range of products in the health care field. The company has three business segments: Consumer, which includes a range of products focused on personal healthcare used in the beauty, over-the-counter pharmaceutical, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension; and Medical Devices, which includes products used in the orthopaedic, surgery, interventional solutions, and eye health fields.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch